

1 **Title**

2 Rapid emergence and transmission of virulence-associated mutations in the oral poliovirus
3 vaccine following vaccination campaigns

4 Katharine S. Walter^{1*}, Jonathan Altamirano², ChunHong Huang³, Yuan J. Carrington³, Frank
5 Zhou³, Jason R. Andrews⁴, Yvonne Maldonado^{3,4}

6 1. Division of Epidemiology, University of Utah, Salt Lake City, UT 84105, USA

7 2. Department of Epidemiology and Population Health, Stanford University School of
8 Medicine, Stanford, CA 94305, USA

9 3. Department of Pediatrics, Stanford University School of Medicine, Stanford, CA,
10 USA

11 4. Division of Infectious Diseases and Geographic Medicine, Stanford University
12 School of Medicine, Stanford, CA 94305, USA

13 *Corresponding Author

14 **Email:** Katharine.Walter@hsc.utah.edu

15 **Author Contributions:** YM, JRA, and KSW designed the study. JA, CH, YC, and FZ
16 conducted DNA extractions, sample preparation, Sanger sequencing, and data management. KW
17 performed data analysis and drafted the paper. YM and JRA reviewed the paper and supervised
18 the project.

19 **Competing Interest Statement:** All authors declare no competing interests.

20 **Classification:** epidemiology, poliovirus

21 **Keywords:** poliovirus, vaccines, virus evolution, transmission, environmental surveillance

22

23

24 **Abstract**

25

26 There is an increasing burden of circulating vaccine-derived polioviruses (cVDPVs) due
27 to the continued use of oral poliovirus vaccine (OPV). However, the informativeness of routine
28 OPV VP1 sequencing for the early identification of viruses carrying virulence-associated
29 reversion mutations has not been directly evaluated in a controlled setting. We prospectively
30 collected 15,331 stool samples to track OPV shedding from vaccinated children and their
31 contacts for ten weeks following an immunization campaign in Veracruz State, Mexico and
32 sequenced VP1 genes from 358 samples. We found that OPV was genetically unstable and
33 evolves at an approximately clocklike rate that varies across serotypes and by vaccination status.
34 Alarming, 28% (13/47) of OPV-1, 12% (14/117) OPV-2, and 91% (157/173) OPV-3 of Sabin-
35 like viruses had ≥ 1 known reversion mutation. Our results suggest that current definitions of
36 cVDPVs may exclude circulating virulent viruses that pose a public health risk and underscore
37 the need for intensive surveillance following OPV use.

38

39 **Introduction**

40 The global use of oral poliovirus vaccine (OPV), a live, attenuated virus, has been
41 essential in reducing the burden of poliomyelitis caused by wild poliovirus by 99.9% since
42 1988^{1,2}. The vaccine covers all three wild poliovirus serotypes, is inexpensive, easy to deliver,
43 and—because it is a live virus—is transmissible from vaccinated children onwards, extending
44 the reach of vaccination campaigns. However, OPV vaccination is risky—the vaccine virus is
45 genetically unstable and continues to evolve in vaccinated individuals and their contacts. If OPV
46 mutates at positions responsible for attenuation of the vaccine virus, it can regain virulence. OPV

47 can regain virulence within a vaccinated individual, causing vaccine-associated paralytic
48 poliomyelitis, though rarely³. OPV may also revert to virulence over transmission chains,
49 generating outbreaks of circulating vaccine derived polioviruses (cVDPVs).

50 To reduce the risks of cVDPVs, in May 2016, trivalent OPV vaccines (containing
51 serotypes 1, 2, and 3) were replaced with a bivalent OPV (containing serotypes 1 and 3),
52 following World Health Organization recommendations. The WHO recommended that routine
53 immunization with at least one dose of inactivated poliovirus vaccine (IPV) prior to the switch to
54 bivalent OPV, to increase protection against paralytic disease⁴. However, access to IPV was
55 limited, leaving large populations of children immunologically naïve to poliovirus type 2. Since
56 the global switch to bivalent OPV, the majority of paralytic poliovirus cases are now caused by
57 cVDPVs, not wild poliovirus, the majority of which are serotype 2 viruses (cVDPV2). From
58 2016 to 2022, type 2 cVDPVs emerged 68 times in 34 countries, leading to more than 1500 cases
59 of paralytic polio⁵ (Fig. 1).

60 The current public health response to outbreaks of cVDPV type 2 is vaccination with
61 monovalent OPV-2 (mOPV-2), to increase population-level immunity and reduce transmission
62 risk. However, the outbreak response itself is risky, as mOPV-2 use can generate new cVDPV
63 outbreaks.

64 Outbreak responses are guided by routine testing of cases of acute flaccid paralysis in
65 children less 15 and environmental surveillance in more than 30 high-risk countries and
66 sequencing of the poliovirus VP1 gene⁶. The Global Polio Eradication Initiative (GPEI) defines
67 VDPVs by their divergence from OPV in the VP1 gene⁶. cVDPVs are defined by evidence of
68 VDPV transmission, through genetically linked viruses from individuals with acute flaccid
69 paralysis or environmental samples⁶ and assigned to new or existing genetic clusters^{7,8}. The

70 identification of new cVDPVs results in an epidemiological investigation and an immunization
71 response⁶.

72 Previous genomic studies of type 2 cVDPVs and OPV-2 shedding in vaccinated children
73 and contacts have identified strong within-host selection and tight transmission bottlenecks that
74 govern the early evolution of type 2 viruses away from the Sabin vaccine strain along a
75 predictable pathway to virulence^{11,12}. Yet previous studies have not yet integrated detailed
76 molecular and epidemiological data to assess the use of VP1 sequencing for the early
77 identification of viruses posing a public health risk. Given that global surveillance and outbreak
78 responses rely on VP1 sequencing, we need a better understanding of how informative VP1
79 diversity is for characterizing risk of reversion to virulence and transmission of virulent viruses.

80 Here, we followed the evolution and transmission of the three OPV serotypes during a
81 prospective study of OPV shedding following a vaccine campaign in semi-rural communities in
82 Veracruz State, Mexico¹³. We sequenced OPV VP1 genes from stool sampled from vaccinated
83 children, their household contacts, and community members in unvaccinated households for 10
84 weeks following the vaccination campaign. This provides a rare opportunity to observe the early
85 evolution and transmission of the three OPV serotypes following vaccination campaigns and to
86 evaluate the current use of VP1 sequencing as an epidemiological tool.

87

88 **Methods**

89

90 *Prospective sampling*

91 We conducted a prospective study of OPV shedding and transmission following a
92 trivalent OPV vaccination campaign during Mexico's February 2015 National Health Week in

93 three semi-rural populations in Orizaba, Veracruz State¹³ (Fig. 2). Wild poliovirus has not been
94 reported since 1994 in Mexico. Mexico's national vaccine program has included routine IPV as
95 well as two annual OPV vaccination campaigns since 2007 and therefore provides a model for
96 transmission of OPV in a setting with routine IPV immunization, an epidemiological context
97 which will increasingly exist as IPV replaces OPV and OPV is only used as a tool for cVDPV or
98 wild poliovirus outbreak response.

99 We randomized 466 households to the vaccine and no-vaccine arm of our study across
100 three communities which were assigned to OPV vaccination rates of 10%, 30%, and 70%. In
101 total, 155 children (8.5% of the population) were vaccinated with trivalent OPV during the
102 National Health Week. Vaccinated children and their household contacts were followed
103 prospectively and stool was collected from all members of sampled households 1 day prior to
104 the National Health Week OPV immunization campaign, and 1, 4, 7, 10, 14, 21, 28, 51, and 71
105 days following, for a total of 10 samples per person¹³. Study nurses collected immunization
106 histories and additional demographic and clinical metadata from all study participants.

107 The study was approved by the Stanford University Institutional Review Board (Protocol
108 #31546), the Comité de Etica, Bioseguridad e Investigación of the Instituto Nacional de Salud
109 Pública (CI: 1260, No. 1581), and the Instituto Veracruzano para la Formación e Investigación
110 en Salud (SESVER/IVEFIS//SIS/DIB/0109/02014, classification 15S).

111
112 *Sanger sequencing of VP1 gene*

113 We extracted RNA from frozen stool samples and tested samples for OPV with serotype-
114 specific RT-qPCR^{13,14}. We Sanger sequenced the VP1 gene using the Y7 and Q8R primers¹⁵ and

115 generated consensus sequences by aligning forward and reverse sequences to serotype-specific
116 reference genomes in *Geneious* v7.

117

118 *Bioinformatic analysis*

119 We aligned VP1 gene sequences of each OPV serotype to the corresponding Sabin
120 vaccine sequence (GenBank Accession Numbers: AY184219, AY184220, AY184221) with
121 MAFFT v.7¹⁶, with the algorithm recommended for closely related viral sequences
122 (<https://mafft.cbrc.jp/alignment/software/closelyrelatedviralgenomes.html>), preserving the
123 alignment length of the reference sequence. We used the default alignment strategy and a
124 nucleotide sequence scoring matrix of 1PAM / $\kappa=2$, recommended for closely related DNA
125 sequences.

126 We quantified pairwise distances between samples with the R package *ape* (pairwise
127 deletion = TRUE)¹⁷. For household contacts and community members who were not vaccinated
128 with OPV, we measured time since vaccination as the time since vaccination of the household
129 member or the earliest vaccination given in the community, respectively. We visualized
130 haplotype networks built from minimum spanning trees with the R package *pegas*¹⁸.

131

132 *Data availability.*

133 The full-length VP1 sequences used in our study are publicly available on GenBank
134 (Submission 2683280, 2683353, and 2683683). The reference sequences used for sequence
135 alignment are publicly available on GenBank (AY184219, AY184220, AY184221). Multiple
136 sequence alignments and metadata to reproduce figures and analyses are publicly available on
137 GitHub (<https://github.com/ksw9/opv-consensus>).

138

139

140 *Code availability.*

141 Code for analysis and figures is publicly available on GitHub

142 (<https://github.com/ksw9/opv-consensus>).

143

144 *Global poliovirus data.*

145 We accessed World Health Organization poliovirus case data from the WHO extranet

146 (<https://extranet.who.int/polio/public/CaseCount.aspx>), including both global and country-level

147 reported cases from 2000-2022.

148

149 **Results**

150

151 **Sample collection**

152 During a prospective study of OPV shedding following a National Health Week

153 vaccination campaign in Veracruz State, Mexico, we collected 15,331 stool samples over 10

154 weeks following vaccination. From these samples, 551 samples were positive for at least one

155 OPV serotype, including 267 OPV-1, 402 OPV-2, and 317 OPV-3 positive samples. We

156 sequenced 358 high quality VP1 genes from 174 individuals, including 18.4% (49/267) positive

157 OPV-1 samples, 33.8% (136/402) positive OPV-2 samples, and 54.5% (173/317) OPV-3

158 samples. Sequence data was available for 99 vaccinated children, 41 household contacts of

159 vaccinated children, 31 members of the community outside of vaccinated households, and 3

160 individuals without known vaccination status. For 84 infections (unique individuals and

161 serotypes), longitudinal samples were available at 2-5 sampling points. The prospective study
162 was conducted in three semi-rural villages; samples include 106 individuals from Capoluca,
163 where 70% of children less than five in participating households were vaccinated; 49 from
164 Campo Grande, where 30% were vaccinated; and 19 individuals from Tuxpanguillo, where 10%
165 were vaccinated.

166

167 **Genetic instability of OPV**

168 We observed a rapid rise of VP1 diversity in all three serotypes over weeks following
169 OPV vaccination. The most common haplotype for both OPV-1 and OPV-2 in each sampling
170 location represents the Sabin vaccine strain (Fig. 3), with a star-like pattern in the haplotype
171 networks, where most haplotypes are directly connected to the Sabin haplotype. Outside of the
172 dominant haplotype, most haplotypes are represented by a single sample.

173 In contrast, for OPV-3, the dominant haplotype differs by a single nucleotide
174 polymorphism (SNP) from the vaccine strain, a previously described attenuating site, C2493U
175 (Fig. 3). Again, there is a star-like pattern of OPV-3 diversity, with many branches stemming
176 directly from the dominant haplotype. As with OPV-2 and OPV-3, most haplotypes outside the
177 dominant haplotype are represented by a single sample.

178

179 **Clock-like early evolution of OPV following vaccination campaigns**

180 The Global Polio Eradication Initiative (GPEI) defines VDPVs by their divergence from
181 the Sabin vaccine in the VP1 gene (>1% divergent or ≥ 10 substitutions for serotypes 1 and 3,
182 0.6% divergent or ≥ 6 substitutions for serotype 2)⁶. The majority, 99% (337/340), of all samples
183 sequenced following vaccination fell under the thresholds for a VDPV. However, two samples

184 from vaccinated children, collected 4 days after vaccination met the definition of a VDPV2 (VP1
185 genetic distance 14 and 8 SNPs from Sabin 2) and one sample from a household contact sampled
186 30 days following vaccination met the definition of a VDPV1 (10 SNPs distant from Sabin 1)
187 (Fig. 4).

188 We then examined if the early evolution of OPV follows a molecular clock and, therefore, if
189 OPV divergence from Sabin vaccine strains could be used to estimate the duration of viral
190 circulation. Genetic divergence of OPV-1 was significantly associated with time following
191 vaccination in both vaccinated children ($p < 0.001$, Pearson's $r = 0.42$) and non-vaccinated
192 individuals ($p < 0.001$, Pearson's $r = 0.90$) (Fig. 4). When considering all samples together, the
193 observed mutations in OPV-1 corresponded to a VP1 gene evolutionary rate of 1.2×10^{-4}
194 substitutions per site per day. Genetic divergence of OPV-2 was not significantly associated with
195 time following vaccination in vaccinated children ($p=0.3$, Pearson's $r = -0.11$) and was positively
196 correlated with time among non-vaccinated individuals, though not significantly so ($p = 0.07$,
197 Pearson's $r = 0.31$) (Fig. 4). OPV-3 divergence was positively associated with time following
198 vaccination for non-vaccinated individuals ($p = 0.007$, Pearson's $r = 0.48$), but not vaccinated
199 children ($p = 0.26$, Pearson's $r = -0.1$)

200 We reasoned that mutations at known attenuating positions may be under strong selection
201 and could affect an estimate of molecular clock. However, excluding the known attenuating sites
202 in the VP1 gene did not substantially change observed associations between genetic divergence
203 and time (Fig. S1).

204

205 **Moderate signal of recent transmission in OPV VP1 gene sequence diversity**

206 VP1 genetic diversity is also used by the GPEI to determine if a VDPV is genetically
207 linked to previously collected environmental or clinical samples, which makes it a cVDPV, and
208 whether viruses are linked to a previously identified cVDPV emergence or constitute a new
209 emergence.

210 To test whether VP1 sequence divergence is genetically structured and could provide
211 evidence of
212 recent transmission, as is done with several pathogens, we compared pairwise genetic distances
213 across samples. As expected with the relatively short duration of sampling following vaccination
214 campaigns, 28.9% (694/2400) of OPV-1; 40.6% (67,16/16,504) of OPV-2; and 42.0%
215 (12,498/29,974) of OPV-3 VP1 pairs of sequences were identical. Mean pairwise distance was
216 2.4 SNPs for OPV-1, 1.5 SNPs for OPV-2, and 1.4 SNPs for OPV-3 (Fig. 5).

217 In a general linear model, pairwise genetic distance between VP1 samples was elevated
218 for individuals from the same household (aOR: 1.29; 95% CI: 1.11-1.50), from the same
219 community (aOR: 1.49; 95% CI: 1.34-1.64), and from different communities (aOR: 1.63; 95%
220 CI: 1.48-1.80), compared to samples collected from an individual. As expected, longitudinal
221 samples from an individual were mostly conserved over the sampling time. Genetic structure
222 varied across serotypes: compared to OPV-1, we observed decreased pairwise genetic distances
223 for both OPV-2 (aOR: 0.64; 95% CI: 0.62-0.65) and OPV-3 (aOR: 0.58; 95% CI: 0.57-0.60).

224

225 **Rapid loss of OPV attenuating mutations in the VP1 gene following vaccination campaigns**

226 We then examined known mutations at key attenuating sites in the vaccine virus,
227 associated with the reversion of vaccine viruses to virulence. Of three known virulence
228 attenuating substitutions in the OPV-1 VP1 gene, 16% (8/49) of samples had a A2749G (Sabin

229 to virulent wildtype) mutation, including 4 vaccinated children and 2 household contacts. The
230 mutation first appeared 14 days following vaccination in a vaccinated child and contact in one
231 house and in another vaccinated child independently and rose in frequency, although there were
232 limited OPV-1 samples available 4+ weeks after vaccination. It was observed in stool up to 52
233 days after the vaccination campaign. A single sample shed by a vaccinated child harbored a
234 A2795G substitution, and no U2879C attenuating mutations occurred (Fig. 6).

235 Among OPV-2 samples, the known VP1 reversion mutation, U2909C/A, occurred in
236 4.4% (6/136) of samples, in four vaccinated children. The substitution was first observed 7 to 14
237 days after vaccination; two children shed OPV-2 carrying this reversion mutation on multiple
238 days. The mutation was observed in stool up to 21 days following the vaccination campaign,
239 though again, there were limited OPV-2 samples available 4+ weeks after vaccination. No
240 individuals had mutations present at the adjacent site 2908, also associated with reversion¹⁹.

241 Among OPV-3 samples, the majority, 91% (157/173), had a C2493A/G/U eversion
242 substitution and an additional 11 samples had a mixed allele or no allele call at that site, possibly
243 evidence of mixed infection. Samples with a C2493A/G/U mutation included 95% (89 of 94) of
244 individuals with OPV-3 sequences available, including 63 vaccinated children, 18 household
245 members, and 8 individuals outside of vaccinated households. The mutation first appeared one
246 day following the vaccination in vaccinated children, household members, and individuals
247 outside vaccinated households and it was observed in stool up to 72 days after the vaccination
248 campaign from a vaccinated child and 70 and 54 days from virus shed in a household member
249 and community member, respectively.

250

251 **Discussion**

252 Global poliovirus surveillance uses molecular epidemiology to directly guide outbreak
253 responses. However, the informativeness of the routinely sequenced marker gene, VP1, in the
254 early identification of VDPVs posing a public health risk has not been evaluated in a controlled
255 setting.

256 Here, we leveraged OPV sampled for 10 weeks following an immunization campaign in a
257 population previously vaccinated with IPV to assess the epidemiological information within VP1
258 samples. We found that all three OPV serotypes are genetically unstable in the weeks following
259 vaccination campaigns, consistent with previous reports. We identified evidence of clocklike
260 VP1 evolution across serotypes (though this signal differed by vaccine status) and significant
261 genetic structure. However, we found evidence of frequent reversion substitutions among viruses
262 classified as Sabin-like, suggesting that current definitions of cVDPVs may exclude circulating
263 viruses that have regained key virulence-associated mutations and which may pose a public
264 health risk.

265

266 *VP1 informativeness*

267 Polioviruses are among the fastest evolving RNA viruses and we observed that the rapid
268 generation of genetic diversity in vaccinated children and their household and community
269 contacts contains epidemiological information. Early evolution of OPV is largely clocklike, with
270 variation in mutation rate across serotypes. The lack of a signal of clocklike evolution of OPV-2
271 and OPV-3 in vaccinated children likely reflects the shorter sampling period for vaccinated
272 children; unvaccinated household and community contacts were infected later in the study by
273 vaccine-derived viruses which had already passed through at least one host.

274 Our estimate of the OPV-1 VP1 substitution rate of 1.2×10^{-4} substitutions/site/day
275 (including all samples) was similar to previous estimates of OPV-1 evolution 0.83×10^{-4}
276 substitutions/site/day²⁰ (estimated from three years of surveillance for acute flaccid paralysis)
277 and faster than the estimate of the molecular clock for wild poliovirus type 1 evolution of $0.28 \times$
278 10^{-4} substitutions/site/day, estimated from a set of 31 viruses sampled over ten years¹⁰. The
279 differences in substitution rate may reflect the different sampling durations, as shorter sampling
280 durations often yield higher pathogen substitution rates estimates, likely because purifying
281 selection has not yet removed transient deleterious mutations are still present prior to the effect
282 of purifying selection^{21,22}. It is also likely that Sabin vaccine viruses evolve more rapidly than
283 wildtype viruses.

284 We observe moderate genetic structure in VP1 sequences, with increasing genetic
285 divergence between samples from different communities compared to that sampled within the
286 same community, household, or longitudinally within an individual. Yet VP1 divergence is not
287 sufficient to make predictions about transmission linkage. Whole genome sequences and
288 additional epidemiological information about timing of infection and contacts could improve
289 inference of transmission networks.

290

291 *Reversion to virulence*

292 The rapid reversion to virulence of Sabin vaccines is well documented²³⁻²⁵. While each
293 serotype has key attenuating mutations in the IRES, additional mutations along the genome,
294 including in the VP1 gene, stabilize the attenuated phenotype²⁶. In OPV-2, a predictable
295 evolutionary route towards virulence includes gatekeeper mutations including an IRES mutation,

296 followed by a VP1 gene mutation, and a reversion in the 5' UTR, followed by a wave of
297 recombination events^{27,28}.

298 We found a high frequency of attenuating substitutions in VP1, with substitutions
299 appearing early after vaccination. The higher frequency of OPV-2 and OPV-3 reversion
300 mutations we observed could reflect the greater observed genetic stability of OPV-1, which
301 differs from the virulent wild-type progenitor virus by 59 substitutions, compared to OPV-2 and
302 OPV-3 which are more closely related to the virulent ancestor²⁹. Our group previously found that
303 97% of OPV-3 recipients shed viruses that had a site 472 reversion mutation within two weeks
304 following vaccination^{30,31}. The instability of OPV-3 has epidemiological consequences: OPV-3
305 causes the majority of vaccine-associated paralytic poliomyelitis (VAPP), paralysis attributable
306 to the vaccine itself, followed by OPV-2 and then OPV-1³.

307 However, previous studies have reported heterogeneity at the OPV-3 C2493U attenuating
308 mutation in vaccine stocks³². We did not have access to vaccine stocks and therefore cannot
309 determine if the near-fixation of an attenuating mutation we observe was due to heterogeneity in
310 the vaccine or *de novo* evolution in vaccinated children and subsequent onwards transmission.

311

312 *Identifying viruses of public health concern*

313 Although the majority of OPV samples in our study collected were defined as Sabin-like
314 viruses, rather than VDPVs, based on sequence divergence, many of the Sabin-like viruses had
315 rapidly lost attenuating mutations at previously described positions. While VP1 sequence
316 divergence may be useful in estimating duration of circulation or predicting transmission cluster,
317 OPV circulating for short periods, that does not yet meet GPEI definitions for a cVDPV, can be
318 virulent and can pose a public health risk in populations without prior immunity. For example,

319 Sabin-like OPV-2 viruses, which were 3 SNPs distant to the Sabin virus VP1 sequence, were
320 previously found to have caused a cluster of acute flaccid paralysis cases in an orphanage in
321 Altai Region of Russia³³. All outbreak genomes shared 15 substitutions compared to the Sabin
322 virus, including the loss of attenuation mutations A481G and U2909C.



323 The global increase of cVDPV2 outbreaks has increased dramatically since 2016, when
324 Sabin 2 was removed from the trivalent poliovirus vaccine⁵. Our results are consistent with
325 previous work on the genetic instability of OPV and rapid reversion to virulence. Our finding
326 that current definitions of cVDPVs may exclude virulent Sabin-like viruses underscores the
327 urgency in heightened surveillance during and following vaccination campaigns.

328

329 **Funding Information**


330 This project was funded by the National Institutes of Health 5R21AI148810 to YM. KSW was
331 funded by a Thrasher Early Career Award and a Stanford Child Health Research Institute
332 postdoctoral fellowship.

333 **Figure 1. The increasing global burden of vaccine-derived poliovirus.** (a) Confirmed cases of
334 paralytic polio reported to the World Health Organization from 2000-2022. Color indicates source:
335 circulating vaccine derived poliovirus (cVDPV) and wild poliovirus cases. (b) Map of countries reporting
336 cVDPV cases in from 2020-2022; fill indicates number of cVDPV cases identified. Data from the World
337 Health Organization.
338




339

340 **Figure 2. Prospective study of OPV shedding among vaccinated children, household members, and**
341 **community members following a vaccination campaign.** (a) Map of Mexico with Veracruz State
342 highlighted and Orizaba city, where the study took place, indicated with a red point. (b) We conducted a
343 prospective observational study of OPV viral shedding following a vaccination campaign. 155 children
344 were enrolled and vaccinated with trivalent OPV. Stool was collected from vaccinated children,
345 unvaccinated household members, and community members in unvaccinated households. We extracted
346 RNA from stool samples, tested samples with OPV serotype-specific RT-PCR, and Sanger sequenced
347 positive samples.




348
349

350 **Figure 3. Limited overall genetic diversity in sampled OPV viral capsid protein 1 (VP1) gene**
351 **following vaccination campaigns.** For each OPV serotype and sampling site, haplotype networks of
352 OPV VP1 representing sampled genetic diversity. Nodes indicate identical haplotypes (VP1 consensus
353 sequences) and node size indicates the number of samples sharing a haplotype. Points on edges between
354 nodes indicate the SNP distance between haplotypes and node colors indicate individual's vaccination
355 status. Labels indicate OPV serotype and study site. Site C, Capoluca, had 70% vaccination coverage of
356 eligible children; site CG, Campo Grande: 30%; site T, Tuxpanguillo: 10%. One sample with a distant
357 haplotype (>14 SNPs distant to the Sabin vaccine) was removed from OPV-2 site C, to aid visualization.




358

359 **Figure 4. Measurable evolution in the OPV VP1 gene following vaccination campaigns.** Genetic
 360 distance of the OPV VP1 gene to the Sabin vaccine strain versus time from vaccination for vaccinated
 361 children (blue) and not vaccinated study participants, including household contacts and unvaccinated
 362 community members (red), for each OPV serotype (a-c). Black lines and grey shading of a linear model
 363 for distance to the Sabin strain. Days following vaccination is measured as days from first vaccination
 364 (for vaccinated children), day from first household vaccination (for non-vaccinated household members),
 365 and days from first community vaccination (for non-vaccinated community members). Red dashed lines
 366 indicate the genetic distance threshold for a cVDPV: 10 SNPs distant from the Sabin vaccine for
 367 serotypes 1 and 3 and 6 SNPs distant for serotype 2.
 368



369


370 **Figure 5. Moderate genetic structure of OPV VP1 gene from samples shed two months following**
371 **vaccination campaigns.** The proportion of pairs of OPV VP1 sequences within a given, binned pairwise
372 genetic distance for samples collected longitudinally from the same individual, from the same household,
373 the same community, or outside the community. Facets indicate OPV serotype.



374
375

376 **Figure 6. Loss of OPV attenuating mutations following vaccination.** For each serotype, points indicate
377 the revertant proportion, the proportion of samples with a mutation at a key attenuating position in OPV
378 in the weeks following vaccination. Bars indicate the total number of sequences available for that
379 sampling week. Each serotype has unique attenuating sites.


380



381
382

383 **Supplementary Figures**

384
 385 **Figure S1. Measurable evolution in the OPV VP1 gene following vaccination campaigns when**
 386 **excluding attenuating mutations.** Genetic distance of the OPV VP1 gene to the Sabin vaccine strain
 387 versus time from vaccination for vaccinated children (blue) and not vaccinated study participants (red),
 388 for each OPV serotype (a-c). Black lines and grey shading of a linear model for distance to the Sabin
 389 strain. Days following vaccination is measured as days from first vaccination (for vaccinated children),
 390 day from first household vaccination (for non-vaccinated household members), and days from first
 391 community vaccination (for non-vaccinated community members). Red dashed lines indicate the genetic
 392 distance threshold for a cVDPV: 10 SNPs distant from the Sabin vaccine for serotypes 1 and 3 and 6
 393 SNPs distant for serotype 2.



394

- 395 1. Khan, F. et al. Progress Toward Polio Eradication — Worldwide, January 2016–March 2018.
396 *Morb. Mortal. Wkly. Rep.* **67**, 524 (2018).
- 397 2. Jorba, J. et al. Update on Vaccine-Derived Poliovirus Outbreaks — Worldwide, January 2018–
398 June 2019. *Morb. Mortal. Wkly. Rep.* **68**, 1024 (2019).
- 399 3. Platt, L. R., Estivariz, C. F. & Sutter, R. W. Vaccine-Associated Paralytic Poliomyelitis: A Review
400 of the Epidemiology and Estimation of the Global Burden. *J. Infect. Dis.* **210**, S380–S389 (2014).
- 401 4. Chumakov, K. M., Brechot, C., Gallo, R. C. & Plotkin, S. Choosing the Right Path toward Polio
402 Eradication. *NEJM* **388**, 577–579 (2023).
- 403 5. Macklin, G. R. et al. Epidemiology of type 2 vaccine-derived poliovirus outbreaks between 2016
404 and 2020. *Vaccine* (2022) doi:10.1016/j.vaccine.2022.08.008.
- 405 6. Global Polio Eradication Initiative. *Classification and reporting of vaccine-derived polioviruses*
406 *(VDPV) - GPEI guidelines*. [http://polioeradication.org/wp-content/uploads/2016/09/Reporting-](http://polioeradication.org/wp-content/uploads/2016/09/Reporting-and-Classification-of-VDPVs_Aug2016_EN.pdf)
407 [and-Classification-of-VDPVs_Aug2016_EN.pdf](http://polioeradication.org/wp-content/uploads/2016/09/Reporting-and-Classification-of-VDPVs_Aug2016_EN.pdf) (2016).
- 408 7. Jorgensen, D., Pons-Salort, M., Shaw, A. G. & Grassly, N. C. The role of genetic sequencing and
409 analysis in the polio eradication programme. *Virus Evol.* **6**, (2020).
- 410 8. Jorba, J. Phylogenetic analysis of poliovirus sequences. *Methods Mol. Biol.* **1387**, 227–237 (2016).
- 411 9. Burns, C. C. et al. Multiple Independent Emergences of Type 2 Vaccine-Derived Polioviruses
412 during a Large Outbreak in Northern Nigeria. *J. Virol.* **87**, 4907–4922 (2013).
- 413 10. Jorba, J., Campagnoli, R., De, L. & Kew, O. Calibration of Multiple Poliovirus Molecular Clocks
414 Covering an Extended Evolutionary Range. *J. Virol.* **82**, 4429–4440 (2008).
- 415 11. Valesano, A. L. et al. The Early Evolution of Oral Poliovirus Vaccine Is Shaped by Strong
416 Positive Selection and Tight Transmission Bottlenecks. *Cell Host Microbe* **29**, 32-43.e4 (2021).
- 417 12. Stern, A. et al. The Evolutionary Pathway to Virulence of an RNA Virus. *Cell* **169**, 35-46.e19
418 (2017).
- 419 13. Sarnquist, C. et al. Protocol Paper: Oral Poliovirus Vaccine Transmissibility in Communities After
420 Cessation of Routine Oral Poliovirus Vaccine Immunization. *Clin. Infect. Dis.* **67**, S115–S120
421 (2018).
- 422 14. Troy, S. B. et al. Use of a novel real-time PCR assay to detect oral polio vaccine shedding and
423 reversion in stool and sewage samples after a mexican national immunization day. *J. Clin.*
424 *Microbiol.* **49**, 1777–83 (2011).
- 425 15. Kilpatrick, D. R. et al. Poliovirus serotype-specific VP1 sequencing primers. *J. Virol. Methods*
426 **174**, 128–130 (2011).
- 427 16. Nakamura, T., Yamada, K. D., Tomii, K. & Katoh, K. Parallelization of MAFFT for large-scale
428 multiple sequence alignments. *Bioinformatics* **34**, 2490–2492 (2018).
- 429 17. Paradis, E. & Schliep, K. Ape 5.0: An environment for modern phylogenetics and evolutionary
430 analyses in R. *Bioinformatics* **35**, 526–528 (2019).
- 431 18. Paradis, E. pegas: an {R} package for population genetics with an integrated--modular approach.
432 *Bioinformatics* **26**, 419–420 (2010).
- 433 19. Wahid, R. et al. Genetic and phenotypic stability of poliovirus shed from infants who received
434 novel type 2 or Sabin type 2 oral poliovirus vaccines in Panama: an analysis of two clinical trials.
435 *The Lancet Microbe* **3**, e912–e921 (2022).
- 436 20. Famulare, M. et al. Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-
437 Like Poliovirus Isolates in Nigeria. *J. Virol.* **90**, 317–331 (2016).
- 438 21. Duchêne, S., Holmes, E. C. & Ho, S. Y. W. Analyses of evolutionary dynamics in viruses are
439 hindered by a time-dependent bias in rate estimates. *Proc. R. Soc. B Biol. Sci.* **281**, (2014).
- 440 22. Holmes, E. C. Molecular Clocks and the Puzzle of RNA Virus Origins. *J. Virol.* **77**, 3893 (2003).
- 441 23. Kew, O. M., Sutter, R. W., de Gourville, E. M., Dowdle, W. R. & Pallansch, M. A. VACCINE-
442 DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO
443 ERADICATION. *Annu. Rev. Microbiol.* **59**, 587–635 (2005).
- 444 24. Duintjer Tebbens, R. J. et al. Oral poliovirus vaccine evolution and insights relevant to modeling
445 the risks of circulating vaccine-derived polioviruses (cVDPVs). *Risk Anal.* **33**, 680–702 (2013).

- 446 25. Burns, C. C., Diop, O. M., Sutter, R. W. & Kew, O. M. Vaccine-derived polioviruses. *J. Infect.*
447 *Dis.* **210**, S283–S293 (2014).
- 448 26. Kew, O. M., Sutter, R. W., De Gourville, E. M., Dowdle, W. R. & Pallansch, M. A. Vaccine-
449 Derived Polioviruses and the Endgame Strategy for Global Polio Eradication *. (2005)
450 doi:10.1146/annurev.micro.58.030603.123625.
- 451 27. Stern, A. et al. The Evolutionary Pathway to Virulence of an RNA Virus. *Cell* **169**, 35-46.e19
452 (2017).
- 453 28. Valesano, A. L. et al. The Early Evolution of Oral Poliovirus Vaccine Is Shaped by Strong
454 Positive Selection and Tight Transmission Bottlenecks. *Cell Host Microbe* **29**, 32-43.e4 (2021).
- 455 29. Kew, O. M., Sutter, R. W., De Gourville, E. M., Dowdle, W. R. & Pallansch, M. A. Vaccine-
456 derived polioviruses and the endgame strategy for global polio eradication. *Annual Review of*
457 *Microbiology* vol. 59 587–635 (2005).
- 458 30. Gnanashanmugam, D. et al. Shedding and Reversion of Oral Polio Vaccine Type 3 in Mexican
459 Vaccinees: Comparison of Mutant Analysis by PCR and Enzyme Cleavage to a Real-Time PCR
460 Assay. *J. Clin. Microbiol.* **45**, 2419 (2007).
- 461 31. Martinez, C. V. et al. Shedding of Sabin poliovirus type 3 containing the nucleotide 472 uracil-to-
462 cytosine point mutation after administration of oral poliovirus vaccine. *J. Infect. Dis.* **190**, 409–
463 416 (2004).
- 464 32. Neverov, A. & Chumakov, K. Massively parallel sequencing for monitoring genetic consistency
465 and quality control of live viral vaccines. *Proc. Natl. Acad. Sci. U. S. A.* **107**, 20063–20068 (2010).
- 466 33. Korotkova, E. A. et al. A Cluster of Paralytic Poliomyelitis Cases Due to Transmission of Slightly
467 Diverged Sabin 2 Vaccine Poliovirus. *J. Virol.* **90**, 5978 (2016).
468